Welcome to our dedicated page for Adlai Nortye news (Ticker: ANL), a resource for investors and traders seeking the latest updates and insights on Adlai Nortye stock.
Adlai Nortye Ltd. reports clinical-stage biotechnology developments for an oncology pipeline focused on RAS-targeting therapies and next-generation cancer immunotherapies. Company updates include clinical and research activity for AN9025, an oral pan-RAS(ON) inhibitor, AN4035, a CEACAM5-targeting antibody-drug conjugate with a pan-RAS(ON) inhibitor payload, AN8025, a tri-functional fusion protein, and AN4005, an oral small-molecule PD-L1 inhibitor.
Recurring news for ANL also covers scientific presentations, license agreements, private-placement financing, shareholder and governance matters, investor conference participation, and American depositary share capital-structure disclosures tied to the company’s foreign-issuer reporting profile.
Adlai Nortye (NASDAQ: ANL) reported its unaudited first half 2024 financial results and recent operational progress. Key highlights include:
1. Appointment of Roger Sawhney, M.D. to the Board of Directors
2. Encouraging safety and efficacy data for AN4005, an oral PD-L1 inhibitor
3. On track to report Phase 3 OS data for buparlisib in Q1 2025
4. Cash and cash equivalents of $98.0 million as of June 30, 2024
5. Net loss decreased by 64.8% to $27.7 million for H1 2024
6. R&D expenses decreased by 4.5% to $26.0 million
7. G&A expenses decreased by 9.8% to $4.7 million
The company remains focused on advancing its pipeline of targeted and immune-modulating cancer therapies.
Adlai Nortye (NASDAQ: ANL), a global clinical-stage biotechnology company, has appointed Roger Sawhney, M.D. to its Board of Directors, effective August 8, 2024. Dr. Sawhney brings nearly 30 years of financial and strategic expertise in the biopharma industry. He currently serves as the Chief Financial Officer of LB Pharmaceuticals and has held leadership positions at various pharmaceutical and investment firms, including Garuda Therapeutics, Omega Therapeutics, KKR & Co. Inc., and Novartis AG.
CEO Carsten Lu welcomed Dr. Sawhney, highlighting his valuable financial experience from both pharmaceutical corporate and healthcare investment perspectives. Dr. Sawhney expressed enthusiasm for joining Adlai Nortye's mission to develop innovative cancer therapies and transform deadly cancer into a chronic and eventually curable disease.
Adlai Nortye (NASDAQ: ANL) has announced its plans to present preliminary data of AN0025 in combination with definitive chemoradiotherapy (dCRT) at the ASCO 2024 Annual Meeting in Chicago from May 31 to June 4, 2024. AN0025, a selective EP4 inhibitor, has shown antitumor activity by modulating macrophages and immunosuppressive myeloid cells. The study, AN0025S0104, is a single-arm, open-label, multicenter, Phase Ib trial, assessing the safety, tolerability, and feasibility of AN0025 plus dCRT for unresectable locally advanced or recurrent esophageal cancer (EC) and esophagogastric junction cancer. Previous studies highlighted the synergistic efficacy of AN0025 with CRT in rectal cancer. Adlai Nortye aims to address unmet patient needs through innovative oncology research.
Adlai Nortye announced the dosing of the first patient in its Phase II clinical trial, named ARTEMIS, for palupiprant (AN0025) in treating locally advanced rectal cancer. This study, led by the Cancer Research UK Clinical Trials Unit at the University of Leeds, aims to compare total neoadjuvant therapy (TNT) with or without AN0025 in patients with moderate to high-risk rectal cancer. The trial involves 140 patients, divided into two groups, and will evaluate clinical complete response (cCR) rate six months post-radiotherapy. The trial builds on encouraging Phase Ib results and seeks to improve efficacy while minimizing invasive surgeries.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.